1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Alibaba Health Information Technology Limited
  6. Summary
    241   BMG0171K1018

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

(241)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-07-06 am EDT
5.700 HKD   -0.70%
06/30Alibaba Health Information Technology Limited Announces Executive Changes
CI
06/27Hong Kong Hang Seng Up 2.4% on Pandemic, Economy Outlooks
MT
06/22Beijing Mulls Banning Internet Healthcare Firms From Selling Drugs Online
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
06/29/2022 06/30/2022 07/04/2022 07/05/2022 07/06/2022 Date
5.48(c) 5.4(c) 5.48(c) 5.74(c) 5.7 Last
105 225 609 73 503 052 61 549 576 116 119 649 94 913 856 Volume
-4.86% -1.46% +1.48% +4.74% -0.70% Change
More quotes
Estimated financial data (e)
Sales 2022 20 318 M 3 024 M 3 024 M
Net income 2022 -480 M -71,4 M -71,4 M
Net cash position 2022 10 549 M 1 570 M 1 570 M
P/E ratio 2022 -132x
Yield 2022 -
Sales 2023 24 982 M 3 718 M 3 718 M
Net income 2023 -292 M -43,5 M -43,5 M
Net cash position 2023 10 598 M 1 577 M 1 577 M
P/E ratio 2023 -65,8x
Yield 2023 -
Capitalization 65 924 M 9 812 M 9 812 M
EV / Sales 2022 2,73x
EV / Sales 2023 2,21x
Nbr of Employees 1 870
Free-Float 34,9%
More Financials
Company
Alibaba Health Information Technology Limited is specialized in the direct sale of pharmaceuticals. The turnover is divided across the following activities: - direct sale of pharmaceuticals (85.2%); - online sale of pharmaceuticals(12.7%); - direct healthcare services (1.8%); - online healthcare services and monitoring of pharmaceuticals (0.3%). The turnover is divided into the revenue sources of product sales... 
More about the company
Ratings of Alibaba Health Information Technology Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
06/30Alibaba Health Information Technology Limited Announces Executive Changes
CI
06/27Hong Kong Hang Seng Up 2.4% on Pandemic, Economy Outlooks
MT
06/22Beijing Mulls Banning Internet Healthcare Firms From Selling Drugs Online
MT
06/22Asian Stock Markets Retreat On Wall Street Cues, Beijing Tech Oversight
MT
06/22Hong Kong Hang Seng Slumps Anew, Down 2.6% on Tech-Sector Outlook
MT
06/22Hong Kong Stocks Snap Three-Day Rally; Mega Genomics Wipes Out Early Gains in Debut
MT
06/22China shares fall on economic outlook, HK down on signs of tech crackdown
RE
06/22Chinese Online Health Companies Extend Losses Amid Sector Sell-Down
DJ
06/21Hong Kong Hang Seng Up 1.9% on China Outlook
MT
06/17Hong Kong Hang Seng Up 1.1% on Beijing Policy Outlook
MT
06/10Hong Kong Hang Seng Down 0.3% After Soft China Price Reports
MT
06/08Hong Kong Hang Seng Up 2.2% in Tech Rally
MT
06/07Hong Kong Hang Seng Down 0.6% As Tech Rally Stalls
MT
06/07UBS Adjusts CK Infrastructure's Price Target to HK$63 From HK$55, Keeps at Buy
MT
06/07China stocks end higher as easing COVID curbs lift sentiment
RE
More news
News in other languages on ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
06/30Alibaba Health Information Technology Limited annonce des changements de direction
06/27Le Hang Seng de Hong Kong en hausse de 2,4 % en raison de la pandémie et des perspectiv..
06/22Pékin envisage d'interdire aux entreprises de soins de santé sur Internet de vendre des..
06/22Les marchés boursiers asiatiques reculent sous l'effet des indices de Wall Bourse et de..
06/22Les actions de Hong Kong rompent leur rallye de trois jours ; Mega Genomics efface les ..
More news
Analyst Recommendations on ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
More recommendations
Chart ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
Duration : Period :
Alibaba Health Information Technology Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 4,91 CNY
Average target price 5,27 CNY
Spread / Average Target 7,22%
EPS Revisions
Managers and Directors
Shun Yan Zhu Chairman & Chief Executive Officer
Yanwu Tu Senior Finance Director
Di Fan Shen Chief Operating Officer & Executive Director
Tong Luo Independent Non-Executive Director
King On Wong Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED-12.90%9 880
VEEVA SYSTEMS INC.-18.91%32 078
OMNICELL, INC.-36.06%5 154
PRO MEDICUS LIMITED-29.04%3 128
EVOLENT HEALTH, INC.16.23%2 946
SECTRA AB (PUBL)-28.47%2 631